Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Capecitabine in Adjuvant cHCC/CCA
NCT07243951Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Combined hepatocellular-cholangiocarcinoma (cHCC-CC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Recurrence-Free Survival at 24 months. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
Combined hepatocellular-cholangiocarcinoma (cHCC-CC)
Beyond the preview
Go deeper on NCT07243951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07243951.